PuriCore Receives Two U.S. Patents

PuriCore plc

("PuriCore" or the "the Company")

PuriCore Receives Two U.S. Patents Covering Drug Development in Inflammatory Skin Diseases

17 August 2016 - PuriCore plc (AIM: PURI), an emerging specialty biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces that the United States Patent and Trademark Office has issued two new patents to PuriCore in connection with the making and use of hypochlorous acid preparations as a novel immunomodulatory therapy for inflammatory skin disorders.

The patents cover method of production, formulations and method of use of hypochlorous acid at therapeutic drug concentrations for the treatment of a broad range of inflammatory skin diseases, including Atopic Dermatitis.  The patents are numbered 9,381,214 and 9,414,584 and will expire in 2032.

The Company announced in February its new strategic focus on drug development of novel therapies in Dermatology, Ophthalmology and potentially rare diseases. In June, the Company announced a successful Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead candidate PR022, which is being developed for the treatment of Atopic Dermatitis. PuriCore plans to submit an Investigational New Drug (IND) application to the FDA for Atopic Dermatitis in Q1 2017.

Alex Martin, Chief Executive Officer of PuriCore, said: 

"The issuance of these new patents is further evidence of the progress we have made in advancing our new strategic focus as an emerging specialty pharmaceutical company. We are continuing to invest in this platform technology and have additional patents, both issued and pending applications, which further support our development plans. We remain on track to submit our IND for PR022 for Atopic Dermatitis in Q1 2017."

Enquiries:

About PuriCore

PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated a drug development program, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology, Ophthalmology and rare disease.

Forward looking statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.